Michael A. Choti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Michael A. Choti has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Epameinondas Dogeas
Department of Surgery, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9031, USA
5 shared publications John L. Cameron
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA
3 shared publicationsKenzo Hirose
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA
3 shared publicationsTimothy M. Pawlik
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA
3 shared publicationsBarish Edil
The Johns Hopkins Hospital, Baltimore, MD
2 shared publicationsChristopher L. Wolfgang
Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University, Baltimore, MD
2 shared publications
Latest Publications
- 5 July 2017
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 21 (12) , 2132-2134
Hepatoid Adenocarcinoma of Unknown Primary Masquerading as a Pancreatic Tumor
- 5 July 2017
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 21 (12) , 2132-2134
Hepatoid Adenocarcinoma of Unknown Primary Masquerading as a Pancreatic Tumor
- 17 May 2017
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 21 (8) , 1262-1269
Duodenal and Ampullary Carcinoid Tumors: Size Predicts Necessity for Lymphadenectomy
- 17 May 2017
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 21 (8) , 1262-1269
Duodenal and Ampullary Carcinoid Tumors: Size Predicts Necessity for Lymphadenectomy
- 11 November 2015
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 23 (2) , 375-381
Surgical Resection Preferences and Perceptions among Medical Oncologists Treating Liver Metastases from Colorectal Cancer
Liver resection is a key therapeutic strategy to improve survival in patients with colorectal cancer liver metastases. Underutilization may negatively affe
- 11 November 2015
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 23 (2) , 375-381
Surgical Resection Preferences and Perceptions among Medical Oncologists Treating Liver Metastases from Colorectal Cancer
Liver resection is a key therapeutic strategy to improve survival in patients with colorectal cancer liver metastases. Underutilization may negatively affe
- 13 January 2015
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 22 (7) , 2201-2208
The Role of Neoadjuvant Therapy in Characterizing Indeterminate Lung Lesions in Patients with Resectable Colorectal Liver Metastases
Incidental pulmonary lesions are frequently found during the preoperative evaluation of patients considered for resection of colorectal liver metastases (CRLM), and their presence can confound management decisions. This study investigates the role of clinical and radiologic factors, including response to preoperative systemic chemotherapy, in determining the malignant probability of these lesions. Computed tomography (CT) scans of 33 patients with small (≤1 cm) lung lesions undergoing resection for CRLM after preoperative chemotherapy were reviewed. Radiological features were recorded from three sequential CT scans (baseline, postchemotherapy, and follow-up). Malignancy was diagnosed either by resection or serial imaging. Chemotherapy response comparing lung lesions and CRLM was categorized as: (1) concordant or (2) discordant. Chemotherapy response, imaging features, and other clinical factors were evaluated in multivariate analyses as predictors of malignancy. Among the 86 indeterminate lung lesions identified, 23 % (20/86) were found to be metastases on follow-up. Lesions 6–10 mm were more likely to be metastases (odds ratio [OR] = 3.14, p = 0.045), as were lesions located in the lower lobes (OR = 4.50, p = 0.018). Concordant chemotherapy response was found in 13 of 86 (15 %) and was independently associated with metastatic disease (OR = 19.87, p Lesion size, location, and chemotherapy response pattern were independent predictors of malignancy for patients with resectable CRLM and small indeterminate lung lesions. Utilization of preoperative chemotherapy can be a useful method of ruling out pulmonary metastases in these patients.
- 13 January 2015
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 22 (7) , 2201-2208
The Role of Neoadjuvant Therapy in Characterizing Indeterminate Lung Lesions in Patients with Resectable Colorectal Liver Metastases
Incidental pulmonary lesions are frequently found during the preoperative evaluation of patients considered for resection of colorectal liver metastases (CRLM), and their presence can confound management decisions. This study investigates the role of clinical and radiologic factors, including response to preoperative systemic chemotherapy, in determining the malignant probability of these lesions. Computed tomography (CT) scans of 33 patients with small (≤1 cm) lung lesions undergoing resection for CRLM after preoperative chemotherapy were reviewed. Radiological features were recorded from three sequential CT scans (baseline, postchemotherapy, and follow-up). Malignancy was diagnosed either by resection or serial imaging. Chemotherapy response comparing lung lesions and CRLM was categorized as: (1) concordant or (2) discordant. Chemotherapy response, imaging features, and other clinical factors were evaluated in multivariate analyses as predictors of malignancy. Among the 86 indeterminate lung lesions identified, 23 % (20/86) were found to be metastases on follow-up. Lesions 6–10 mm were more likely to be metastases (odds ratio [OR] = 3.14, p = 0.045), as were lesions located in the lower lobes (OR = 4.50, p = 0.018). Concordant chemotherapy response was found in 13 of 86 (15 %) and was independently associated with metastatic disease (OR = 19.87, p Lesion size, location, and chemotherapy response pattern were independent predictors of malignancy for patients with resectable CRLM and small indeterminate lung lesions. Utilization of preoperative chemotherapy can be a useful method of ruling out pulmonary metastases in these patients.
- 22 June 2014
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 15 (3) , 456-464
Liver-Directed Treatments for Metastatic Colorectal Cancer
When possible, surgical resection remains the “gold standard” for the treatment of hepatic colorectal metastases. Liver resection should be considered when complete removal of all macroscopic disease can be achieved safely. For those patients with unresectable metastases, or when a patient may not be a candidate for liver resection, many choices are available to the clinician in an attempt to achieve locoregional control, including tumor ablation, intra-arterial therapies, and radiation therapy. Whereas with surgical resection, durable local control can be considered potentially curable, other liver-directed approaches currently are mostly palliative. Ongoing trials are being undertaken to evaluate the role of such cytoreductive therapies. During the initial evaluation of any patient who might be a candidate for liver-directed therapy, particularly when the intent may be curative, complete assessment with high-quality imaging should be done before any therapy to determine the full extent of disease. Most importantly, the establishment of a multidisciplinary team upon initial diagnosis can optimize the choice and sequencing of the various systemic and locoregional choices available to the colorectal cancer patient.
- 22 June 2014
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 15 (3) , 456-464
Liver-Directed Treatments for Metastatic Colorectal Cancer
When possible, surgical resection remains the “gold standard” for the treatment of hepatic colorectal metastases. Liver resection should be considered when complete removal of all macroscopic disease can be achieved safely. For those patients with unresectable metastases, or when a patient may not be a candidate for liver resection, many choices are available to the clinician in an attempt to achieve locoregional control, including tumor ablation, intra-arterial therapies, and radiation therapy. Whereas with surgical resection, durable local control can be considered potentially curable, other liver-directed approaches currently are mostly palliative. Ongoing trials are being undertaken to evaluate the role of such cytoreductive therapies. During the initial evaluation of any patient who might be a candidate for liver-directed therapy, particularly when the intent may be curative, complete assessment with high-quality imaging should be done before any therapy to determine the full extent of disease. Most importantly, the establishment of a multidisciplinary team upon initial diagnosis can optimize the choice and sequencing of the various systemic and locoregional choices available to the colorectal cancer patient.
- 8 April 2014
- Published by Springer Nature in Current Colorectal Cancer Reports
- Vol. 10 (2) , 218-226
The Evolving Use of Prognostic Factors After Resection of Colorectal Liver Metastases
- 8 April 2014
- Published by Springer Nature in Current Colorectal Cancer Reports
- Vol. 10 (2) , 218-226
The Evolving Use of Prognostic Factors After Resection of Colorectal Liver Metastases
- 1 April 2014
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 218 (4) , 628-635
Alternative Lengthening of Telomeres Predicts Site of Origin in Neuroendocrine Tumor Liver Metastases
The determination of the primary tumor origin in patients with neuroendocrine tumor liver metastases (NELM) can pose a considerable management challenge. Recent studies have shown that the alternative lengthening of telomeres (ALT) is prevalent in some human tumors, including pancreatic neuroendocrine tumors (PanNET), and can be useful in predicting tumor biology. In this study, we aimed to evaluate the use of ALT as a biomarker in patients with NELM, in particular to predict the site of origin of metastases. Tissue microarrays (TMAs) were constructed using tumor tissue from NELM patients undergoing liver resection between 1998 and 2010. These included 43 PanNET and 47 gastrointestinal carcinoid tumors. The TMAs were tested for ALT using telomere-specific fluorescent in situ hybridization. The association between ALT positivity and clinicopathologic features and long-term outcomes was investigated. Alternative lengthening of telomeres was positive (ALT+) in 26 (29%) of the 90 tumors included in the TMAs. Pancreatic neuroendocrine tumors were ALT+ in 56% of patients, compared with only 4% ALT+ among gastrointestinal carcinoid tumors (p < 0.001). The specificity of ALT for detecting pancreatic origin was 96% and the positive predictive value was 92%, and sensitivity was 56% and the negative predictive value was 70%. Additionally, ALT was associated with the pattern of metastatic disease: ALT+ NELM were more likely to have oligometastases (p = 0.001) and less likely to be bilateral in distribution (p = 0.05) than were ALT tumors. In addition, ALT+ was associated with improved prognosis in the PanNET patient population. Alternative lengthening of telomeres was found to be a useful biomarker in patients with NELM. This marker can be helpful in guiding therapy by identifying the site of origin in patients in whom the primary site is unknown.
- 1 April 2014
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 218 (4) , 628-635
Alternative Lengthening of Telomeres Predicts Site of Origin in Neuroendocrine Tumor Liver Metastases
The determination of the primary tumor origin in patients with neuroendocrine tumor liver metastases (NELM) can pose a considerable management challenge. Recent studies have shown that the alternative lengthening of telomeres (ALT) is prevalent in some human tumors, including pancreatic neuroendocrine tumors (PanNET), and can be useful in predicting tumor biology. In this study, we aimed to evaluate the use of ALT as a biomarker in patients with NELM, in particular to predict the site of origin of metastases. Tissue microarrays (TMAs) were constructed using tumor tissue from NELM patients undergoing liver resection between 1998 and 2010. These included 43 PanNET and 47 gastrointestinal carcinoid tumors. The TMAs were tested for ALT using telomere-specific fluorescent in situ hybridization. The association between ALT positivity and clinicopathologic features and long-term outcomes was investigated. Alternative lengthening of telomeres was positive (ALT+) in 26 (29%) of the 90 tumors included in the TMAs. Pancreatic neuroendocrine tumors were ALT+ in 56% of patients, compared with only 4% ALT+ among gastrointestinal carcinoid tumors (p < 0.001). The specificity of ALT for detecting pancreatic origin was 96% and the positive predictive value was 92%, and sensitivity was 56% and the negative predictive value was 70%. Additionally, ALT was associated with the pattern of metastatic disease: ALT+ NELM were more likely to have oligometastases (p = 0.001) and less likely to be bilateral in distribution (p = 0.05) than were ALT tumors. In addition, ALT+ was associated with improved prognosis in the PanNET patient population. Alternative lengthening of telomeres was found to be a useful biomarker in patients with NELM. This marker can be helpful in guiding therapy by identifying the site of origin in patients in whom the primary site is unknown.
- 1 February 2014
- Published by Elsevier in Medical Image Analysis
- Vol. 18 (2) , 314-329
Ultrasound elastography using multiple images
- 1 February 2014
- Published by Elsevier in Medical Image Analysis
- Vol. 18 (2) , 314-329
Ultrasound elastography using multiple images